SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Respiratory Disease
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1753465809352791v1
3/6/267    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Miravitlles, M.
Right arrow Articles by Stauch, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miravitlles, M.
Right arrow Articles by Stauch, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study

Marc Miravitlles

Servei de Pneumologia Institut Clínic del Tòrax Hospital Clínic, Barcelona, Spain, MARCM{at}clinic.ub.es

Antonio Anzueto

University of Texas Health Sciences Centre, South Texan Veterans Health Care System, San Antonio, TX, USA

Santiago Ewig

Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, Herne und Bochum, Germany

Delfino Legnani

Ospedale Luigi Sacco, Milan, Italy

Kathrin Stauch

Bayer Schering Pharma, Bayer Vital GmbH, Leverkusen, Germany

Objective: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin.

Methods: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients’ daily lives.

Results: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days.

Conclusions: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.

Key Words: chronic bronchitis • chronic obstructive pulmonary disease • exacerbations • moxifloxacin • quality of life

This version was published on December 1, 2009

Therapeutic Advances in Respiratory Disease, Vol. 3, No. 6, 267-277 (2009)
DOI: 10.1177/1753465809352791
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement